Propolis and its active component, Caffeic acid phenethyl ester (CAPE), modulate breast cancer therapeutic targets via an epigenetically mediated mechanism of action

Journal of Cancer Science and Therapy

Volumn 5, Issue 10, 2013, Pages 334-342

  Omene, Coral ^a   Kalac, Matko ^a   Wu, Jing ^b   Marchi, Enrica ^a,b,c   Frenkel, Krystyna ^a   O'Connor, Owen A ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Medicine   (United States)

^c Columbia University ^*  (United States)

Author keywords

Breast cancer; CAPE; HDAC inhibitor; Propolis

Indexed keywords

CAFFEIC ACID PHENETHYL ESTER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PANOBINOSTAT; PROGESTERONE RECEPTOR; PROPOLIS;

ARTICLE; BREAST CANCER; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; EPIGENETICS; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE TEST; NORMAL HUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

EID: 84889689157     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000224     Document Type: Article

References (62)

1. Boon H, Brown JB, Gavin A, Kennard MA, Stewart M (1999) Breast cancer survivors' perceptions of complementary/alternative medicine (CAM): making the decision to use or not to use. Qual Health Res 9: 639-653.
2. Crocetti E, Crotti N, Feltrin A, Ponton P, Geddes M, et al. (1998) The use of complementary therapies by breast cancer patients attending conventional treatment. Eur J Cancer 34: 324-328.
3. Sparber A, Bauer L, Curt G, Eisenberg D, Levin T, et al. (2000) Use of complementary medicine by adult patients participating in cancer clinical trials. Oncol Nurs Forum 27: 623-630.
4. Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18: 2505-2514.
5. Morris KT, Johnson N, Homer L, Walts D (2000) A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 179: 407-411.
6. Burdock GA (1998) Review of the biological properties and toxicity of bee propolis (propolis). Food Chem Toxicol 36: 347-363.
7. Lotfy M, Badra G, Burham W, Alenzi FQ (2006) Combined use of honey, bee propolis and myrrh in healing a deep, infected wound in a patient with diabetes mellitus. Br J Biomed Sci 63: 171-173.
8. Castaldo S, Capasso F (2002) Propolis, an old remedy used in modern medicine. Fitoterapia 73 Suppl 1: S1-6.
9. Ansorge S, Reinhold D, Lendeckel U (2003) Propolis and some of its constituents down-regulate DNA synthesis and inflammatory cytokine production but induce TGF-beta1 production of human immune cells. Z Naturforsch C 58: 580-589.
10. Son S, Lewis BA (2002) Free radical scavenging and antioxidative activity of caffeic acid amide and ester analogues: structure-activity relationship. J Agric Food Chem 50: 468-472.
11. Koltuksuz U, Mutu ÅŸHM, Kutlu R, Ozyurt H, Cetin S, et al. (2001) Effects of caffeic acid phenethyl ester and epidermal growth factor on the development of caustic esophageal stricture in rats. J Pediatr Surg 36: 1504-1509.
12. Michaluart P, Masferrer JL, Carothers AM, Subbaramaiah K, Zweifel BS, et al. (1999) Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation. Cancer Res 59: 2347-2352.
13. Borrelli F, Izzo AA, Di Carlo G, Maffia P, Russo A, et al. (2002) Effect of a propolis extract and caffeic acid phenethyl ester on formation of aberrant crypt foci and tumors in the rat colon. Fitoterapia 73 Suppl 1: S38-43.
14. Frenkel K, Wei H, Bhimani R, Ye J, Zadunaisky JA, et al. (1993) Inhibition of tumor promoter-mediated processes in mouse skin and bovine lens by caffeic acid phenethyl ester. Cancer Res 53: 1255-1261.
15. Huang MT, Ma W, Yen P, Xie JG, Han J, et al. (1996) Inhibitory effects of caffeic acid phenethyl ester (CAPE) on 12-O-tetradecanoylphorbol-13-acetate-induced tumor promotion in mouse skin and the synthesis of DNA, RNA and protein in HeLa cells. Carcinogenesis 17: 761-765.
16. Yang C, Wu J, Zhang R, Zhang P, Eckard J, et al. (2005) Caffeic acid phenethyl ester (CAPE) prevents transformation of human cells by arsenite (As) and suppresses growth of As-transformed cells. Toxicology 213: 81-96.
17. Xiang D, Wang D, He Y, Xie J, Zhong Z, et al. (2006) Caffeic acid phenethyl ester induces growth arrest and apoptosis of colon cancer cells via the beta-catenin/T-cell factor signaling. Anticancer Drugs 17: 753-762.
18. Chen MF, Wu CT, Chen YJ, Keng PC, Chen WC (2004) Cell killing and radiosensitization by caffeic acid phenethyl ester (CAPE) in lung cancer cells. J Radiat Res 45: 253-260.
19. Kudugunti SK, Vad NM, Ekogbo E, Moridani MY (2011) Efficacy of caffeic acid phenethyl ester (CAPE) in skin B16-F0 melanoma tumor bearing C57BL/6 mice. Invest New Drugs 29: 52-62.
20. Kuo HC, Kuo WH, Lee YJ, Lin WL, Chou FP, et al. (2006) Inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells in vitro and in vivo. Cancer Lett 234: 199-208.
21. Chen MJ, Chang WH, Lin CC, Liu CY, Wang TE, et al. (2008) Caffeic Acid Phenethyl Ester Induces Apoptosis of Human Pancreatic Cancer Cells Involving Caspase and Mitochondrial Dysfunction. Pancreatology 8: 566-576.
22. Wu CS, Chen MF, Lee IL, Tung SY (2007) Predictive role of nuclear factor-kappaB activity in gastric cancer: a promising adjuvant approach with caffeic acid phenethyl ester. J Clin Gastroenterol 41: 894-900.
23. Onori P, DeMorrow S, Gaudio E, Franchitto A, Mancinelli R, et al. (2009) Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF-kappaB and induction of apoptosis. Int J Cancer 125: 565-576.
24. Lee K, Kang N, Kim J, Lee K, Lee D, et al. (2008) Caffeic acid phenethyl ester inhibits invasion and expression of matrix metalloproteinase in SK-Hep1 human hepatocellular carcinoma cells by targeting nuclear factor kappa B. Genes Nutr 2: 319-322.
25. Wu J, Omene C, Karkoszka J, Bosland M, Eckard J, et al. (2011) Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer. Cancer Lett 308: 43-53.
26. Omene CO, Wu J, Frenkel K (2012) Caffeic Acid Phenethyl Ester (CAPE) derived from propolis, a honeybee product, inhibits growth of breast cancer stem cells. Invest New Drugs 30: 1279-1288.
27. Song SH, Han SW, Bang YJ (2011) Epigenetic-based therapies in cancer: progress to date. Drugs 71: 2391-2403.
28. Yoo CB, Jones PA (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5: 37-50.
29. O'Connor OA, Heaney ML, Schwartz L, Richardson S, Willim R, et al. (2006) Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor SuberoylanilideHydroxamic Acid in Patients With Advanced Hematologic Malignancies. J Clin Oncol 24: 166-173.
30. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, et al. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23: 3923-3931.
31. Wagner JM, Hackanson B, Lübbert M, Jung M (2010) Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 1: 117-136.
32. Davidson NE, Gelmann EP, Lippman ME, Dickson RB (1987) Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1: 216-223.
33. Marks PA, Richon VM, Rifkind RA (2000) Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92: 1210-1216.
34. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, et al. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications. Proc Natl Acad Sci U S A 101: 540-545.
35. Maiso P, Carvajal-Vergara X, Ocio EM, López-Pérez R, Mateo G, et al. (2006) The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 66: 5781-5789.
36. Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27: 5459-5468.
37. Marks PA, Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25: 84-90.
38. Tan J, Cang S, Ma Y, Petrillo RL, Liu D (2010) Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 3: 5.
39. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, et al. (2005) Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33: 53-61.
40. Huang WJ, Lin CW, Lee CY, Chi LL, Chao YC, et al. (2011) NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells. J Ethnopharmacol 136: 156-167.
41. Huang WJ, Liang YC, Chuang SE, Chi LL, Lee CY, et al. (2012) NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity. Evid Based Complement Alternat Med 2012: 781417.
42. Sun LP, Chen AL, Hung HC, Chien YH, Huang JS, et al. (2012) Chrysin: a histone deacetylase 8 inhibitor with anticancer activity and a suitable candidate for the standardization of Chinese propolis. J Agric Food Chem 60: 11748-11758.
43. Zhou Q, Davidson NE (2006) Silencing estrogen receptor alpha in breast cancer cells. Cancer Biol Ther 5: 848-849.
44. Davidson NE (2000) Combined endocrine therapy for breast cancer--new life for an old idea? J Natl Cancer Inst 92: 859-860.
45. Hurvitz SA, Pietras RJ (2008) Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer 113: 2385-2397.
46. Wardley A, Stein R, McCaffrey J, Crown J, Malik Z, et al. (2010) Phase II data for entinostat, a class 1 selective histone deacetylase inhibitor, in patients whose breast cancer is progressing on aromatase inhibitor therapy. J ClinOncol 28: 15s.
47. Yardley DAI-KR, Klein PM (2011) PD01-04: Entinostat, a Novel Histone Deacetylase Inhibitor, Added to Exemestane Improves PFS in Advanced Breast Cancer in a Randomized, Phase II, Double-Blind Study, Cancer Res 71: 5472.
48. Zhou Q, Atadja P, Davidson NE (2007) Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther 6: 64-69.
49. Yang X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, et al. (2001) Synergistic Activation of Functional Estrogen Receptor (ER)-a by DNA Methyltransferase and Histone Deacetylase Inhibition in Human ER-a-negative Breast Cancer Cells. Cancer Res 61: 7025-7029.
50. Jung BI, Kim MS, Kim HA, Kim D, Yang J, et al. (2010) Caffeic acid phenethyl ester, a component of beehive propolis, is a novel selective estrogen receptor modulator. Phytother Res 24: 295-300.
51. Nicholson RI, McClelland RA, Gee JM, Manning DL, Cannon P, et al. (1994) Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. Breast Cancer Res Treat 29: 117-125.
52. Nicholson S, Wright C, Sainsbury JR, Halcrow P, Kelly P, et al. (1990) Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: neu and tamoxifen failure. J Steroid Biochem Mol Biol 37: 811-814.
53. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JMW, et al. (2003) Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells. Endocrinology 144: 1032-1044.
54. Zhou Q, Shaw PG, Davidson NE (2009) Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Res Treat 117: 443-451.
55. Harari D, Yarden Y (2000) Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19: 6102-6114.
56. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
57. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, et al. (1999) Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease. J Clin Oncol 17: 2639.
58. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant Humanized Anti-HER2 Antibody (Herceptin™) Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts. Cancer Res 58: 2825-2831.
59. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 93: 1852-1857.
60. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117-127.
61. Huang X, Gao L, Wang S, Lee CK, Ordentlich P, et al. (2009) HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res 69: 8403-8411.
62. Bali P, Pranpat M, Swaby R, Fiskus W, Yamaguchi H, et al. (2005) Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 11: 6382-6389.